Comments
Drug-maker Granules India’s net profit declined 31 per cent to ₹101 crore in the quarter ended December 31, 2021, against ₹147 crore in the corresponding quarter of the previous year.
The total revenue of the Hyderabad-based company, however, increased 18 per cent to ₹997 crore from ₹845 crore in the same period last year, according to a release.
Commenting on the results, Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India, said, “We are slowly getting back to the normal as is evident from the revenue growth which came in despite the continuing disruptions and challenging environment such as raw material price increase and unstable supply from China, among other supply constraints.’‘
The company is expecting the situation to improve in the coming quarters and would remain focused on execution and agile to the market opportunities, he added.
Granules is “strengthening management capabilities and investing in R&D infrastructure, scientific talent, and partnerships in science & technology which will lead to sustainability, leadership, backward integration and focus on quality of our portfolio,” the release added,
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.